MedTrace Logo

Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI

NCT01681524 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-05-30

No results posted yet for this study

Summary

The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to determine if the study drug in PET imaging is better than SPECT imaging currently used for this purpose.

Conditions

Interventions

DRUG

Flurpiridaz F18

Injection of Flurpiridaz F18 for the purposes of PET MPI analysis

Sponsors & Collaborators

  • Lantheus Medical Imaging

    lead INDUSTRY

Principal Investigators

  • Cesare Orlandi, MD · Lantheus Medical Imaging

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-02-28
Completion
2014-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681524 on ClinicalTrials.gov